![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Cataract is a leading cause of blindness globally, and its surgical treatment poses a significant burden on global healthcare. Pharmacologic therapies, including antioxidants and protein aggregation reversal agents, have attracted great attention in the treatment of cataracts in recent years. Due to the anatomical and physiological barriers of the eye, the effectiveness of traditional eye drops for delivering drugs topically to the lens is hindered. The advancements in nanomedicine present novel and promising strategies for addressing challenges in drug delivery to the lens, including the development of nanoparticle formulations that can improve drug penetration into the anterior segment and enable sustained release of medications. This review introduces various cutting-edge drug delivery systems for cataract treatment, highlighting their physicochemical properties and surface engineering for optimal design, thus providing impetus for further innovative research and potential clinical applications of anti-cataract drugs.
Abbreviations
AgNPs, Silver nanoparticles; AuNPs, Gold nanoparticles; BSA-NPs, Albumin nanoparticles; CeCl3@mSiO2, Cerium chloride-loaded mesoporous silica nanoparticles; CNPs, Cerium oxide nanoparticles; CPPs, Cell-penetrating peptides; CUR, Curcumin; DSF, Disulfiram; GFP, Green fluorescent protein; GSH, Glutathione; LAN, Lanosterol; LAN-NPs/ISG, Lanosterol nanoparticles in situ gel; LCS, L-carnosine; LECs, Lens epithelial cells; MgT, Magnesium taurate; MSNs, Mesoporous silica nanoparticles; NACS, N-acetylcarnosine; Nano-SOD1, Cu/Zn-superoxide dismutase nanoparticles; NFP, Nifedipine; NIL, Nilvadipine; NLCs, nanostructured lipid carriers; PCNPs, Cerium oxide nanoparticles coated with PEG-PLGA; POD, Peptide for ocular delivery; R8, Octa-arginine; ROS, Reactive oxygen species; RSV, Resveratrol; SLNs, Solid lipid nanoparticles; SOD, Superoxide dismutase.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
The authors declare no competing interests in this work.